Biomarker Panel for Chronic Graft-Versus-Host Disease [Hematologic Malignancy]

Conclusion
We conclude that the biomarker panel measured at diagnosis or day +100 after HCT may allow patient stratification according to risk of cGVHD.

Source: Journal of Clinical Oncology - July 19, 2016 Category: Cancer & Oncology Authors: Yu, Storer, Kushekhar, Abu Zaid, Zhang, Gafken, Ogata, Martin, Flowers, Hansen, Arora, Cutler, Jagasia, Pidala, Hamilton, Chen, Pusic, Lee, Paczesny Tags: Leukemia Hematologic Malignancy Source Type: research